Does Caralluma fimbriata extract (Slimaluma) reduce the risk factors of metabolic syndrome in overweight and obese adults?

The effects of Caralluma fimbriata extract (Slimaluma) in combination with lifestyle intervention on the risk factors of metabolic syndrome in overweight and obese adults: a randomised controlled trial

Status

Not yet recruiting

Phases

Phase 4

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12610000289011

Enrollment

Registered

2010-04-09

Start date

2010-05-01

Completion date

Unknown

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

A 3-month intervention using encapsulated Caralluma fimbriata extract in combination with lifestyle intervention to investigate whether or not Caralluma fimbriata extract suppresses the appetite and decreases the risk factors of metabolic syndrome

Interventions

Caralluma fimbriata extract capsule 500mg oral administration, twice per day before meals for three months. Water soluble, Caralluma fimbriata extract containing 27.8% Pregnane Glycosides and 13.3% Saponin Glvcosides. Lifestyle intervention focuses on healthy dietary intake based on the Dietary guidelines for Australian adults for three months.

Study design

Allocation

Randomised controlled trial

Intervention model

Parallel

Primary purpose

Prevention

Masking

Blinded (masking used)

Eligibility

Sex/Gender

All

Age

30 Years to 60 Years

Healthy volunteers

Inclusion criteria

Males and females aged 30-60 years with a body mass index (BMI) greater than 25 or a waist circumference > 94cm for males and >80cm for females.

Exclusion criteria

Liver, kidney and heart disease, pregnancy, type 1 and type 2 diabetes with insulin medication, cigarette smoking and the use of any medication for weight loss.

Outcome results